The short version
- Legal representatives for dozens of families are urging the Lampard inquiry to recommend a nationwide ban on the Oxevision camera system used in English mental health wards.
- Evidence presented suggests the technology may have replaced vital face-to-face care and contributed to five deaths at one trust, while raising significant privacy and data protection issues.
- The manufacturer defends the system as a safety tool, but inquiry statisticians found no evidence supporting its clinical effectiveness, leading to calls for interim regulatory action.
A growing coalition of bereaved families is calling for an immediate halt to the use of intrusive camera monitoring systems in mental health facilities across England. Lawyers representing these relatives appeared before the Lampard inquiry into mental health deaths in Essex, arguing that the continued deployment of the Oxevision system poses a direct threat to patient safety. The legal team contends that the technology, which relies on infrared cameras to monitor patients remotely, has been misapplied in ways that have materially contributed to harm and, in some instances, death.
The inquiry heard testimony regarding five specific cases at the Essex Partnership University NHS foundation trust where patients died by suicide or unexpectedly while under surveillance by Oxevision. These incidents occurred over a two-year period, highlighting what lawyers describe as a pattern of failure rather than isolated errors. Peter Mant KC, representing more than seventy families, emphasized that lives are currently at stake due to the ongoing use of the system. He argued that the technology has frequently served as a substitute for direct human observation, thereby depriving vulnerable individuals of essential therapeutic engagement.
Central to the criticism is the claim that Oxevision creates a coercive environment on psychiatric wards. Brenda Campbell KC, another lead lawyer, described the presence of cameras in patient bedrooms as a significant invasion of privacy that offers no sanctuary. She noted that the technology falls hardest on detained, traumatized, and neurodivergent patients, exacerbating feelings of paranoia and distress. Evidence presented included accounts from families whose loved ones expressed fear of being trapped or spied upon, with some patients reportedly screaming at the devices. This dynamic, lawyers argue, undermines the trust necessary for effective mental health treatment.
Confusion among staff regarding the proper use of the system appears to be a critical factor in its failure. Mant told the inquiry that nursing staff, patients, and hospital managers often lacked clarity on how Oxevision should be integrated into care protocols. This ambiguity led to situations where alarms were muted or ignored, as was the case with Elise Sebastian, a sixteen-year-old who died by suicide in 2021 after staff had disabled the system’s alerts. The families’ representatives stress that the technology is not fit for purpose in its current state and that reliance on it has prevented vital in-person care opportunities.
The manufacturer, Lio, an Oxford-based company, defends the utility of Oxevision. Laura Cozens, the head of patient safety at Lio, testified that the technology assists staff in intervening during critical safety incidents. She urged the inquiry to consider the benefits the system offers and cautioned against interpreting recent evidence as proof that the technology is unsafe or ineffective. However, Mant countered these claims by stating that assertions of effectiveness are based on unverified anecdotes rather than robust data. He pointed out that statisticians employed by the inquiry found no evidence to support the clinical efficacy of the system.
The Lampard inquiry, which began in 2024, is examining more than two thousand mental health deaths in Essex over a twenty-three-year period. It has already heard harrowing evidence of avoidable self-harm and suicides at the Essex trust and its predecessor organizations. Lady Lampard, the chair of the inquiry, is considering issuing interim regulations if she determines that immediate action is necessary to prevent further fatalities. This includes potential restrictions on the use of Oxevision and mandates for life-saving training for all mental health staff.
Beyond the clinical and ethical concerns, there are significant data protection issues surrounding the technology. The Information Commissioner’s Office launched a separate inquiry earlier this year into Oxevision over privacy violations. Campbell highlighted that no regulator had previously taken responsibility for the harms associated with the system, despite its widespread adoption. She noted that the intrusive nature of the cameras has spread to up to fifty percent of NHS trusts, raising questions about how such a controversial tool became so prevalent without adequate oversight or proven benefit.
The families are urging Lady Lampard to conclude that the residual claims of limited clinical benefit do not outweigh the significant harm to patient safety, autonomy, and privacy. They are asking for immediate recommendations to suspend the use of Oxevision and implement mandatory training for staff. The outcome of this inquiry could set a precedent for how technology is integrated into mental health care, balancing innovation with the fundamental rights and safety of some of society’s most vulnerable individuals. As the investigation continues, the focus remains on preventing further avoidable deaths and restoring trust in mental health services.
Sources behind this briefing
Go to the original reporting
- The Guardian World↗Ban ‘intrusive’ cameras on mental health wards in England, say bereaved families
